It is possible that in a subset of individuals, especially those prone to autoimmune disease, the administration of such PTP1B/PTPN2 inhibitors may result in immune-related toxicities, as also seen in patients receiving immune checkpoint therapies58. The gene discussed is PTPN2; the disease is autoimmune disease.